Karyopharm Therapeutics Inc. will present new data on selinexor for treating multiple myeloma and myelofibrosis at the 66th American Society of Hematology (ASH) Annual Meeting, held December 7-10, 2024, in San Diego, CA. The presentations will cover the efficacy and safety of selinexor in combination with pomalidomide and dexamethasone (SPd) for relapsed or refractory multiple myeloma (RRMM), as well as selinexor's impact on hematopoietic stem cells in ruxolitinib-refractory myelofibrosis.
Selinexor in Multiple Myeloma
One presentation will focus on the efficacy and safety of the SPd regimen in patients with RRMM. The study, detailed in Abstract #1996, investigates selinexor in combination with pomalidomide and dexamethasone. This is particularly relevant as multiple myeloma remains a challenging disease with a need for novel treatment options after patients relapse or become refractory to standard therapies.
Selinexor in Myelofibrosis
Another presentation (Abstract #1377) will explore selinexor's mechanism of action in myelofibrosis, specifically its ability to deplete ruxolitinib-refractory hematopoietic stem cells by inducing apoptosis and reducing the pro-inflammatory environment. Myelofibrosis, a serious bone marrow disorder, often becomes resistant to ruxolitinib, highlighting the importance of new therapeutic strategies.
Antengene's Selinexor Data
Antengene, a partner of Karyopharm, will also present data (Abstract #4748) on a Phase 3 trial evaluating weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice-weekly bortezomib and dexamethasone (Vd) in Chinese patients with RRMM. This study provides insights into the potential of selinexor-based combinations in different patient populations and treatment settings.
About Selinexor
Selinexor, marketed as XPOVIO, is a first-in-class, oral exportin 1 (XPO1) inhibitor. It is approved in the U.S. for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, in combination with dexamethasone in heavily pre-treated multiple myeloma, and for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two lines of systemic therapy. Selinexor functions by selectively binding to and inhibiting the nuclear export protein XPO1, which is often dysregulated in cancer cells.
